Peters K, Mücke R, Hamann D, Ziegler P G, Fietkau R
Klinik und Poliklinik für Strahlentherapie, Universität Rostock, Germany.
Strahlenther Onkol. 1999 Nov;175 Suppl 4:23-6.
Amifostine is a new cancer-supporting agent to protect normal tissue in patients receiving radio-chemotherapy. The main question of our study is whether the application of amifostine can be limited on the duration of chemotherapy in patients with advanced head and neck tumors undergoing radio-chemotherapy.
In a randomized study 14 patients were treated with amifostine (500 mg, day 1 to 5 and 29 to 33) during concurrent radio-chemotherapy with carboplatin (70 mg/m2, day 1 to 5 and 29 to 33), 14 patients were treated without amifostine. The analyzed parameters were dermatitis, mucositis, skin temperature, white blood and platelet count, creatinine and scintigram of salivary glands. Median survival of the amifostine group was 19 months, of the control group 10 months.
There were no relevant differences in all analyzed parameters between both arms of the study.
Our form of amifostine application is probably not able to obtain a relevant reduction of the toxicity of radio-chemotherapy.
氨磷汀是一种新型癌症支持药物，用于保护接受放化疗患者的正常组织。我们研究的主要问题是，对于接受放化疗的晚期头颈部肿瘤患者，氨磷汀的应用是否可以限制在化疗期间。
在一项随机研究中，14例患者在同步放化疗期间接受氨磷汀治疗（500毫克，第1至5天和第29至33天），同时使用卡铂（70毫克/平方米，第1至5天和第29至33天），14例患者未接受氨磷汀治疗。分析的参数包括皮炎、粘膜炎、皮肤温度、白细胞和血小板计数、肌酐以及唾液腺闪烁扫描。氨磷汀组的中位生存期为19个月，对照组为10个月。
研究的两组在所有分析参数上均无显著差异。
我们应用氨磷汀的方式可能无法显著降低放化疗的毒性。
